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T
he world is holding its collective breath.
Governments and health organizations are
feverishly preparing, stockpiling drugs and vac-
cines, and formulating contingency plans.
Headlines are coughing out dire predictions of
up to 100 million deaths worldwide and devas-
tating economic consequences. Experts are chill-
ingly warning that it’s not a matter of if, but
when—when a pandemic of avian influenza will
strike the human population. 
Although the H5N1 avian flu is already a
serious problem in Asia, it will not become a
major threat to human health worldwide until
and unless the virus mutates into a strain that is
both highly virulent and highly communicable
from human to human. At present that is not
the case, but influenza viruses are notorious for
their ability to mutate via a process called anti-
genic drift. 
Mutation into a strain with the potential for
pandemic may never happen, but if it does, mortal-
ity could be extremely high. Rapid global travel
could spread the disease quickly, and, unlike with
the seasonal flu strains that come around every
winter, our bodies are not immunologically familiar
with this type of avian influenza—no one will have
native defenses to ward off or minimize infection.
Massive efforts are under way both in the
United States and internationally to respond
should an avian flu pandemic occur. One of the
most important elements in controlling a pandem-
ic will be the development and production of an
effective vaccine. Now Yoshihiro Kawaoka and his
colleagues at the University of Wisconsin–Madison
School of Veterinary Medicine and the University
of Tokyo have perfected an advanced method of
producing the inactivated “seed” virus used to pro-
duce influenza vaccine, a technique known as
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reverse genetics. This breakthrough may
represent a critical step forward in acceler-
ating the production of enough vaccine in
a short enough time to prevent massive
loss of life. 
The Chicken and the Egg
To be effective, the nonvirulent virus used
to make an influenza vaccine must match
the genetic makeup of the viral strain that
is circulating in the human population.
Stimulation of the immune system by
exposure to the nonpathogenic form of
the viral strain produces antibodies that
will confer future resistance to the patho-
genic strain. The key is to
first identify and then recre-
ate the subtypes of two of
the virus’s surface pro-
teins—hemagglutinin (HA)
and neuraminidase (NA).
These are the “active ingre-
dients” of the virus, deter-
mining the strain’s virulence
and communicability, and
are the targets of vaccine
intervention. There are 16
HA subtypes and 9 NA sub-
types—the combination of
these surface protein sub-
types describes the viral
strain (for example, H5N1).
Reassortment, the tradi-
tional method of seed virus
production, has been around
for more than 50 years and
remains in almost universal
use, particularly in the pro-
duction of annual seasonal
flu vaccines. In reassortment,
scientists inject fertilized
chicken eggs with both a
standard nonpathogenic
influenza strain known to
grow well in eggs and the circu-
lating strain that carries the genes
expressing the desired HA and NA pro-
tein subtypes. The two viruses multiply,
and their genes mix with each other in up
to 256 possible combinations of eight
genes each. The resultant viruses are then
screened, with the desired virus being the
one with the six genes that allow the
standard strain to grow so well in eggs
and the HA and NA genes from the cir-
culating strain. This seed virus is then
injected into millions of eggs for mass
production of that year’s vaccine.
Edward Janoff, who is chief of the
infectious diseases division of the
University of Colorado Health Sciences
Center School of Medicine and a mem-
ber of the Infectious Diseases Society of
America Pandemic Influenza Task Force,
describes the reassortment process as “very
tedious.” According to Andrew Pekosz, an
assistant professor of molecular microbiolo-
gy at the Washington University in St.
Louis School of Medicine, the whole
process to generate seed stocks “could take
two weeks optimistically, but more realisti-
cally one to two months.” As Kawaoka
bluntly puts it, “Classical reassortment? I
don’t know why people are still using that
method.”
Monkeying Around with Plasmids
Kawaoka and his colleagues were among
the groups who originally developed
reverse genetics in the 1990s. With the
reverse genetics method, scientists can
splice the desired genes—six from the
harmless strain and the HA and NA genes
from the circulating strain (which have
already been adjusted to be nonviru-
lent)—into small circular pieces of DNA
called “plasmids.” The plasmids are then
transfected into animal cells, and the vac-
cine seed virus grows. The seed stock can
then be grown in mass quantity for vac-
cine production either in the traditional
chicken egg or in cell culture. 
Although the laboratory techniques
used in reverse genetics are fairly routine at
Using Reverse Genetics to Produce Vaccinethis point, safety and efficiency issues have
presented obstacles to it completely sup-
planting the reassortment method. The first
challenge was the safety of the animal cell
line itself. Researchers were concerned that
the cells could cause cancer or carry other
dangerous viruses. But now a line of African
green monkey kidney cells known as Vero
cells has been cleared for use in reverse
genetics. “These Vero cells have been vetted
fairly carefully to be safe,” says Janoff, “and
the cell line has now been approved for pro-
duction of human viruses.”
The second obstacle was the difficulty
of transfecting the cell line with plasmids
and growing enough virus to be of use as
seed stock. “Many of these cell lines that
we’d like to use in a cell culture–based vac-
cine are very hard to transfect with plas-
mids,” says Karen Lacourciere, an influenza
program officer at the National Institute of
Allergy and Infectious Diseases. Until now,
it was thought to be necessary to transfect
eight to twelve plasmids carrying the various
viral elements into the Vero
cells, and results have been
less than ideal in terms of
the efficiency of viral res-
cue—that is, the generation
of sufficient numbers of
viruses for vaccine use. It
can and has been done; the
H5N1 vaccine currently in
clinical trials (based upon
the existing H5N1 strain)
was the first one developed
via reverse genetics. But
clearly, reverse genetics has
not been quite ready for
prime time.
The refinement to reverse
genetics that Kawaoka and
colleagues describe in the
15 November 2005 edition
of the Proceedings of the
National Academy of Sciences
overcomes this second hur-
dle. The advance is quite sim-
ple. Kawaoka’s group has
shown that by combining the
viral elements in certain ways,
the number of plasmids
needed to generate large
amounts of virus in Vero cells
can be reduced. In short, the
team tried several different
combinations of genes and
numbers of plasmids, until
they narrowed down which
one seemed to work the best
in terms of virus production. 
Four plasmids appears to
be the ideal number: “If we
don’t worry about just gener-
ation of virus, we can make a virus with one
plasmid,” says Kawaoka. “But in a practical
sense, we would use four plasmids, and we
would be changing only one plasmid, which
encodes HA and NA genes. . . . Our method
simply allows one to make vaccine candidate
strains easily, so any laboratory can now easi-
ly make any H5N1-containing strain.”
A Small Step with Big Implications
Kawaoka is modest about the achieve-
ment, but observers see it as a crucial step
forward. “This new reverse genetics system
will allow a cell culture–based vaccine
strategy to be developed and become more
efficient,” says Lacourciere. This is partic-
ularly good news given certain problems
associated with the egg production sys-
tem—the need for huge quantities of eggs,
and the fact that a significant number of
people are allergic to eggs (although no
prevalence studies have been done on the
general population, 1.5% of children
under age 3 are known to have this aller-
gy, according to The Food Allergy &
Anaphylaxis Network).
Should a pandemic avian flu strain
emerge, time will be of the essence. “What
this [method] allows you to do,” says
Pekosz, “is generate the seed stock for a
pandemic virus twenty-four hours after the
pandemic is detected—it could speed up
the process that quickly.”
Janoff, who has his finger on the pulse
of preparations for a pandemic, agrees.
“One of the concerns about a pandemic is
that it would spread more quickly than a
regular flu,” he says. This means vaccine
producers would have a shorter window of
time from selecting the virus to having
enough vaccine on hand for people both at
the source of the epidemic and across the
globe as the disease spreads. “So if you can
reduce the time from identification and
selection to actual vaccine,” he says, “that
would really potentially save millions of
lives.”
If and when the H5N1 virus mutates
into a strain that retains its lethal effects and
becomes highly transmissible from human
to human, the clock will start ticking, and
the race against time to control the pan-
demic will begin. Thanks to Kawaoka and
his colleagues, at least now the human race
will have a bit of a head start.
Ernie Hood
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Egg-citing approach to producing vaccines. Yoshihiro
Kawaoka (right) and lab technician Barry McClernon (left) over-
see an experiment in Kawaoka's laboratory at the UW–Madison
School of Veterinary Medicine, where they are working to
refine vaccine manufacturing technologies to ensure a faster
response to flu outbreaks.
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